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Abstract
Purpose Elevated plasma concentration of retinol binding protein 4 (RBP4) has recently emerged as a potential risk factor 
as a component of developing metabolic syndrome (MS). Therefore, this study aimed to analyse the relationship between 
components  of MS and concentrations of plasma RBP4 in a population of subjects 65 years and older.
Methods The study sample consisted of 3038 (1591 male) participants of the PolSenior study,  aged 65 years and older. 
Serum lipid profile, concentrations of RBP4, glucose, insulin, C-reactive protein, IL-6, and activity of aminotransferases were 
measured. Nutritional status (BMI/waist circumference) and treatment with statins and fibrates were evaluated. Glomerular 
filtration rate (eGFR), de Ritis ratio, and fatty liver index (FLI), as well as HOMA-IR were calculated.
Results Our study revealed a strong relationship between components of MS and RBP4 in both sexes: plasma RBP4 levels 
were increased in men by at least 3×, and in women by at least 4×. Hypertriglyceridemia was most strongly associated with 
elevated plasma RBP4 levels. Multivariate, sex-adjusted regression analysis demonstrated that chronic kidney disease [OR 
1.86 (95% CI 1.78–1.94)], hypertriglyceridemia [OR 1.52 (1.24–1.87)], hypertension [OR 1.15 (1.12–1.19)], low serum 
HDL cholesterol [OR 0.94 (0.92–0.97)], and age > 80 years [OR 0.86 (0.81–0.90)] were each independently associated with 
RBP4 concentration (all p < 0.001).
Conclusions In Caucasians 65 years and older, RBP4 serum levels are associated with a number of components of MS, 
independent of sex and kidney function. Hypertriglyceridemia as a component of MS is most significantly related to RBP4 
concentration.
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Introduction
Metabolic syndrome (MS) is a set of abnormalities which 
include visceral obesity, carbohydrate metabolism distur-
bances or type 2 diabetes, hypertriglyceridemia, decreased 
HDL cholesterol levels, and elevated blood pressure, 
[1–5]. Numerous studies have shown that the occurrence 
of components of MS significantly increases the risk of 
type 2 diabetes, cardiovascular diseases, and mortality in 
middle-aged populations [6–10].
Insulin resistance related to visceral obesity is the major 
pathway in the pathogenesis of MS [1–5]. Increased vol-
ume of visceral adipocytes is associated with local inflam-
mation, followed by changes in adipokine release by vis-
ceral adipose tissue and low grade systemic inflammation. 
Both endocrine dysfunction of adipose tissue and systemic 
inflammation promote development of insulin resistance.
It has been shown that retinol binding protein 4 (RBP4) 
is one of the adipokines that participates in the develop-
ment of insulin resistance by impairing insulin signalling 
at both the receptor and post-receptor levels, as well as 
by stimulation of liver gluconeogenesis [11]. The primary 
sources of RBP4 in vivo are hepatocytes and adipocytes 
[12]. Higher plasma RBP4 levels were reported in insulin-
resistant humans and mice [11, 13] as well as patients with 
type 2 diabetes [11, 14], hypertriglyceridemia [15], athero-
genic dyslipidaemia [16, 17], and hypertension [18–20].
Plasma RBP4 level correlates with abdominal fat vol-
ume [21], waist circumference, BMI, and WHR [22, 23]. 
Stefan et al. [24] demonstrated that RBP4 level is mainly 
associated with the amount of fat in the liver and pre-
sumably with hepatic insulin resistance. In addition, a 
stronger correlation was observed between RBP4 levels 
and HOMA-IR values than that between RBP4 and waist 
circumference [14]. Finally, RBP4 level has been consid-
ered by some researchers to be a predictor of MS devel-
opment in children [25, 26] and adults, and may be a new 
target for MS therapy [27].
The association between plasma RBP4 levels and BMI, 
HOMA-IR, or other components of MS in obese patients is 
questioned by some researchers [15], while other research-
ers demonstrate correlation with BMI only in crude com-
parison and not in models adjusted for age and sex (for 
example: the Third Generation Framingham Heart Study 
cohort [28]). In addition, some authors have shown a 
strong association between circulating RBP4 levels and the 
number of MS components [29, 30], while others indicated 
that age influences the association between RBP4 and MS 
components [31].
So far, no studies have assessed the relationship 
between RBP4 levels and components of MS in older 
adults. Hence, the aim of this study was to evaluate if 
there is a relationship between circulating RBP4 levels 
and components of MS in a large (65+), population-based 
Polish cohort.
Methods
Study design and setting
The PolSenior study, performed in the years 2007–2012, 
recruited six, similarly sized, age cohorts (65–69, 70–74, 
75–79, 80–84, 85–89, 90 years and older). During three vis-
its performed by specially trained nurses, a questionnaire 
survey, comprehensive geriatric assessment, and measure-
ments of body mass, height, waist circumference, and blood 
pressure were performed [32]. The current sub-study was 
based on data of 3038 available plasma samples stored at 
− 70 °C that were obtained from all project participants 
65 years old and above in the morning after an overnight 
fast.
Measurements
Height and body mass were measured with the subjects 
wearing light clothes and no shoes (Tanita scale BC-536, 
Tokyo, Japan) with an accuracy of 0.5  cm and 0.1  kg, 
respectively. The body mass index (BMI) was calculated 
according to the standard formula.
Waist circumference was measured midway between 
the last rib and the iliac crest in a standing position with 
the anterior axillary line guiding the tape-measure near the 
umbilicus with an accuracy of 0.5 cm.
Blood pressure (BP) measurement was performed on the 
right upper arm, three times, in the sitting position after a 
5-min rest using a fully automatic oscillometric BP meas-
uring device accurate to 1 mm Hg (A&D Medical, Tokyo, 
Japan), with the cuff selected according to the arm circum-
ference. Thirty min before BP readings, the subjects did 
not smoke cigarettes, drink coffee, or engage in physical 
exercise [33]. Mean value was calculated from two BP 
measurements.
Laboratory parameters
Plasma RBP4 concentrations were measured by ELISA 
(Immundiagnostik AG, Bensheim, Germany) with a 0.9-pg/
mL limit of sensitivity and with mean intra- and inter-assay 
coefficients of < 5.0 and < 9.8%, respectively. The standard 
range in adults reported by the manufacturer is 20–75 µg/
mL.
Serum insulin concentration was assessed by electro-
chemiluminescence immunoassay (ECLIA) using com-
mercially available kits on a Cobas E411 analyser (Roche 
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Diagnostics GmbH, Mannheim, Germany) with an inter-
assay coefficient of variability of < 3.8%. Plasma interleu-
kin-6 (IL-6) was measured by ELISA (R&D Systems, Min-
neapolis, MN, USA) with a sensitivity of 0.04 pg/mL and 
mean intra-assay and inter-assay coefficient of variance < 7.8 
and < 7.2%, respectively.
Serum total cholesterol, LDL cholesterol, HDL cho-
lesterol, triglycerides, glucose, albumin, creatinine, and 
C-reactive protein concentrations, and activity of alanine 
(ALT), aspartate (AST) transaminases, and gamma-glutamyl 
transpeptidase (GGT) were previously assessed by an auto-
mated system (Modular PPE, Roche Diagnostics GmbH, 
Mannheim, Germany) in a single certified laboratory with 
inter-assay coefficients of variability below 1.7, 1.2, 1.3, 1.8, 
1.7, 1.7, 2.3, 5.7, 4.4, 3.2, and 1.4%, respectively.
Data analysis
Components of MS were diagnosed according to the IDF 
modified criteria [34]. Any three of the following compo-
nents present in an individual warranted the diagnosis of 
MS: 1. visceral obesity for Europeans (waist circumference 
≥ 94 cm in men and ≥ 80 cm in women), 2. serum triglycer-
ide level ≥ 1.7 mmol/L or treatment of hypertriglyceridemia, 
3. low serum HDL-cholesterol concentration < 1.03 mmol/L 
in men and < 1.29 mmol/L in women or treatment of this 
condition, 4. systolic blood pressure ≥ 130 mm Hg or/and 
diastolic blood pressure ≥ 85 mm Hg or previously diag-
nosed hypertension, 5. fasting plasma glucose ≥ 5.6 mmol/L 
or previously diagnosed type 2 diabetes.
Insulin resistance was assessed by HOMA-IR calculated 
with a standard formula. The de Ritis ratio (AST/ALT) was 
calculated and values greater than 1 were considered to be 
a surrogate marker of liver damage. Fatty Liver Index (FLI) 
was calculated according to the equation derived from the 
population of the Dionysos Nutrition & Liver Study [35]; 
a score of 60 points or greater denoted hepatic steatosis. 
Glomerular filtration rate (eGFR) was estimated according 
to the MDRD formula [36].
Statistical analysis
Statistical analysis was performed using STATISTICA 
10.0 PL (StatSoft, Tulsa, OK, US) and StataSE 12.0 
(StataCorp LLC, College Station, TX, US). Statistical sig-
nificance was set at a p value below 0.05. All tests were 
two-tailed. Nominal and ordinal data were expressed as 
percentages, while interval data were expressed as the 
mean value ± standard deviation in the case of a normal 
distribution or as median (lower quartile–upper quartile) 
in the case of data with skewed or non-normal distribu-
tion. Distribution of variables was evaluated by the Sha-
piro–Wilk test and quantile–quantile (QQ) plots. The 
Levene test assessed homogeneity of variances. To evalu-
ate the relationship between variables and RBP4 serum 
levels in three groups according to tertiles, the one-
way ANOVA with Dunnett’s post hoc test and two-way 
ANOVA (metabolic syndrome components and sex) with 
contrast analysis were used. The stepwise backwards mul-
tivariate ordinal logistic regression was used to assess fac-
tors influencing RPB4 serum levels. Comparison of data 
in ordinal and nominal scale was made either with the χ2 
test or χ2 trend test.
Results
RBP4 serum levels
Similar plasma RBP4 levels were found in men and 
women (medians: 41.3 vs. 41.0 ng/mL, p = 0.96). There-
fore, lower and upper tertiles were calculated jointly for 
men and women after logarithmic conversion because of 
heavy-skewed RBP4 distribution (below 33, between 33 
and 51, and over 51 ng/mL). Regardless of similar RBP4 
values, but due to the differentiated distribution of compo-
nents of MS between men and women, univariate analyses 
were done separately for men and women.
Factors affecting plasma RBP4 concentration
In the RBP4 tertile groups (Table 1), significant differ-
ences in the occurrence  of hypertension and chronic 
kidney disease (CKD), serum triglyceride levels, GGT 
activity, FLI, and eGFR values were found in both men 
and women. Additionally, statistically relevant differ-
ences in diastolic blood pressure, type 2 diabetes occur-
rence, serum glucose level, and the de Ritis ratio > 1 were 
noted between tertile groups only in women. Differences 
found only in men included the usage of fibrates (highest 
in the upper tertile) and serum levels of total and LDL 
cholesterol.
Multivariate stepwise ordered logistic regression analy-
sis of factors influencing RBP4 levels revealed that chronic 
kidney disease had the strongest influence both in crude and 
sex-adjusted analyses. Other factors that positively corre-
lated with RBP4 levels after sex adjustment were hypertri-
glyceridemia and a higher systolic BP. An inverse relation-
ship was observed in the crude model for subjects in excess 
of 80 years of age and decreased serum HDL cholesterol 
concentration or its treatment. After sex adjustment, the de 
Ritis ratio > 1 lost statistical relevance. Likelihood of fatty 
liver, expressed as FLI > 60, did not correlate with RBP4 
levels (Table 2).
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Table 1  Results of one-way ANOVA analysis separate for men and women in three groups according to RBP4 serum level tertiles
RBP4 tertile Women Men
Lower n = 483 Middle n = 486 Upper n = 478 P Lower n = 530 Middle n = 527 Upper n = 534 P
Age, years 78 ± 9 78 ± 9 77 ± 8 0.49 79 ± 8 79 ± 9 78 ± 8 0.12
Age ≥ 80 years, 
n (%)
186 (38.5) 171 (35.2) 178 (37.2) 0.56 228 (43.0) 228 (43.3) 208 (38.9) 0.28
BMI (kg/m2) 28.7 ± 5.7 28.9 ± 5.2 29.5 ± 5.5 0.10 27.3 ± 4.4 27.1 ± 4.2 27.6 ± 4.8 0.31
Obesity, n (%) 186 (38.5) 193 (39.7) 202 (42.3) 0.48 130 (24.5) 126 (23.9) 143 (26.8) 0.52
Waist circumfer-
ence (cm)
96.2 ± 13.5 96.1 ± 13.3 97.1 ± 13.4 0.45 100.0 ± 12.7 100.2 ± 12.9 101.4 ± 12.5 0.17
Systolic BP 
(mmHg)
144.6 ± 21.4 147.5 ± 21.2 145.6 ± 22.0 0.10 143.2 ± 20.1 144.5 ± 23.0 146.3 ± 22.5 0.07
Diastolic BP 
(mmHg)
84.2 ± 10.6 86.2 ± 10.8* 85.0 ± 11.1 < 0.05 80.6 ± 11.0 81.5 ± 11.6 81.6 ± 11.6 0.28
Hypertension, 
n (%)
360 (74.5) 379 (78.0) 390 (81.6)** < 0.01$ 344 (64.9) 364 (69.1) 391 (73.2)** < 0.01$
Type 2 diabetes, 
n (%)
106 (21.9) 115 (23.7) 139 (29.1)** < 0.01$ 107 (20.2) 119 (22.6) 111 (20.8) 0.61
Serum glucose 
(mmol/L)
93.8 (84.5–
105.7)
95.1 (86.3–
107.0)
96.8 (86.9–
110.0)*
< 0.05 94.7 (86.5–
106.4)
96.0 (86.5–
109.3)
96.1 (87.3–
107.4)
0.39
Insulin, µIU/mL 12.0 (8.4–17.8) 11.7 (8.1–17.4) 13.0 (8.6–18.9) 0.08 9.8 (6.6–15.1) 10.7 (6.9–15.8) 10.8 (7.3–16.1) 0.09
HOMA-IR 2.82 (1.83–
4.22)
2.80 (1.74–
4.51)
3.10 (1.90–
4.78)
0.61 2.34 (1.41–
3.79)
2.50 (1.53–
4.25)
2.60 (1.59–
4.10)
0.10
HOMA-IR ≥ 2.5, 
n (%)
286 (59.2) 274 (56.4) 297 (62.1) 0.19 245 (46.2) 261 (49.5) 274 (51.3) 0.24
ALT, U/L 19.7 (16.1–
23.4)
19.7 (16.6–
23.3)
19.0 (16.0–
23.0)
0.55 19.5 (16.1–
23.0)
19.9 (16.6–
24.0)
20.2 (17.2–
24.0)
0.15
AST, U/L 9.7 (7.2–13.1) 10.0 (7.6–13.4) 9.9 (7.4–13.1) 0.55 10.2 (7.8–13.8) 10.9 (8.0–14.8) 10.8 (8.0–14.5) 0.15
GGT, U/L 16.6 (11.2–
25.5)
16.0 (11.7–
25.0)
18.0* (12.7–
26.6)
< 0.05 18.6 (13.3–
29.0)
21.0 (14.5–
31.1)
22.4# (15.8–
35.0)
< 0.001
de Ritis ratio 0.51 (0.39–
0.66)
0.52 (0.39 
–0.66)
0.51 (0.40–
0.67)
0.71 0.54 (0.41–
0.67)
0.54 (0.40–
0.71)
0.54 (0.41–
0.69)
0.79
de Ritis > 1, n 
(%)
14 (2.9) 19 (3.9) 31 (6.5)** < 0.05 23 (4.3) 30 (5.7) 30 (5.6) 0.54
Fatty liver index 
(FLI)
49.1 ± 28.8 50.4 ± 29.1 54.6 ± 29.2** < 0.01 48.5 ± 27.9 49.9 ± 27.2 54.6 ± 27.8# < 0.001
FLI > 60, n (%) 185 (38.3) 201 (41.4) 223 (46.7)** < 0.05 201 (38.0) 194 (36.9) 237 (44.4)** < 0.05
Total cholesterol, 
mmol/L
211.0 ± 45.6 213.9 ± 46.7 211.4 ± 51.8 0.59 187.4 ± 39.8 198.4 ± 45.1# 196.6 ± 44.4** < 0.001
LDL cholesterol, 
mmol/L
125.0 ± 40.4 126.5 ± 39.6 123.6 ± 43.9 0.54 111.9 ± 35.7 120.7 ± 39.0# 115.4 ± 37.8 < 0.001
HDL cholesterol, 
mmol/L
53.0 ± 13.8 53.9 ± 14.1 53.3 ± 14.8 0.58 48.2 ± 12.6 48.7 ± 13.7 48.3 ± 13.5 0.79
Triglycerides, 
mmol/L
115.6 (89.2–
150.0)
121.0 (91.6–
161.3)
129.3# (98.3–
167.5)
< 0.001 98.5 (75.1–
131.3)
104.5* (84.2–
135.1)
113.6# (88.7–
153.9)
< 0.001
Statins, n (%) 114 (23.6) 121 (24.9) 138 (28.9) 0.15 112 (21.1) 117 (22.2) 139 (26.0) 0.14
Fibrates, n (%) 7 (1.4) 3 (0.6) 9 (1.9) 0.21 2 (0.4) 7 (1.3) 12 (2.2) < 0.05
hs-CRP, mg/L 2.3 (1.1–5.0) 2.4 (1.2–4.5) 2.5 (1.3–4.6) 0.76 2.3 (1.0–5.2) 2.0 (0.9–4.9) 2.3 (1.0–5.0) 0.43
hs-
CRP ≥ 3 mg/L, 
n (%)
205 (42.4) 200 (41.1) 207 (43.3) 0.79 222 (41.9) 207 (39.3) 214 (40.1) 0.67
Interleukin 6, pg/
mL
2.2 (1.5–3.7) 2.2 (1.4–3.4) 2.0 (1.4–3.4) 0.34 2.6 (1.6–4.3) 2.4 (1.6–3.8) 2.2 (1.3–3.8) 0,08
eGFRMDRD mL/
min/1.73 m2
79.9 ± 20.6 75.5 ± 19.6# 77.3 ± 22.8# < 0.001 82.7 ± 20.0 77.9 ± 19.8# 75.1 ± 23.8# < 0.001
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RBP4 and MS components
Our study revealed a strong relationship between compo-
nents of MS and RBP4, both in women (p < 0.01) and men 
(p < 0.001). Hypertriglyceridemia (p < 0.001 for both sexes), 
occurrence of type 2 diabetes or fasting plasma glucose over 
100 mg/dL (p < 0.01, p < 0.05 for women and men, respec-
tively) were substantially related to RBP4 levels (Table 3).
RBP4 and the number of components of MS
Two-way ANOVA was run to examine how the number of 
components of MS and sex influence the RBP4 serum levels. 
There was no significant interaction between the number of 
components of MS and sex (p = 0.88). Simple main effects 
analysis showed a significant association of the number 
of components of MS (p < 0.001) with the level of RBP4, 
but there were no differences between men and women 
(p = 0.39) (Fig. 1).
In comparison to the group without MS (less than three 
components of MS), RBP4 serum levels were higher in 
groups with at least three components for men and with at 
least four components for women (Fig. 1).
Discussion
Our large, population-based, cohort study shows that 
increased RBP4 serum levels are strongly associated with 
the presence and the number of components of MS in an 
65 + Caucasian population. These findings correspond with 
previous studies performed in multi-ethnic and over 65-year-
old populations [37–39]. The findings support the hypothesis 
that RBP4 plays a role in the pathogenesis of the metabolic 
complications found in obesity.
Data presented as mean value ± SD or median (lower–upper quartile)
Bold values indicate statistically significant results
BMI body mass index, hs-CRP C-reactive protein, eGFR estimated glomerular filtration rate, HOMA-IR homeostatic model assessment of insu-
lin resistance, ALT alanine transaminase, AST aspartate transaminase
$ For trend; in comparison to the lower quartile: *p < 0.05; ** p < 0.01; #p < 0.001
Table 1  (continued)
RBP4 tertile Women Men
Lower n = 483 Middle n = 486 Upper n = 478 P Lower n = 530 Middle n = 527 Upper n = 534 P
eGFR < 60 mL/
min/1.73 m2, 
n (%)
121 (25.0) 139 (28.6) 185 (38.7)# < 0.001 101 (19.1%) 150 (28.5%)** 178 (33.3%)# < 0.001
Table 2  Results of multivariable stepwise ordered logistic regression analysis of factors influencing plasma RBP4 levels
*p < 0.05; **p < 0.01; #p < 0.001
Factor Crude Sex-adjusted
OR ± 95% CI OR ± 95% CI
Female – – Not considered in the 
model
Age > 80 years 0.862* 0.749–0.991 0.856# 0.813–0.901
Visceral obesity – – – –
Serum triglycerides levels ≥ 150 mg/dL or treatment of hypertriglyceridemia 1.494# 1.281–1.741 1.520# 1.236–1.869
Serum HDL-cholesterol concentration: < 40 mg/dL in men and < 50 mg/dL in women or 
treatment this lipid disturbances
– – 0.944# 0.920–0.967
Systolic blood pressure ≥ 130 mmHg or/and diastolic blood pressure ≥ 85 mmHg or previ-
ously diagnosed hypertension
– – 1.152# 1.116–1.188
Fasting plasma glucose ≥ 100 mg/dL (≥ 5.6 mmol/L) or previously diagnosed type 2 
diabetes mellitus
– – – –
hs-CRP > 3 mg/L – – – –
de Ritis ratio > 1 1.392* 1.021–1.898 – –
FLI: > 60 – – – –
eGFR < 60 mL/min/1.73 m2 1.858# 1.573–2.195 1.861# 1.781–1.944
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In older adults the association between RBP4 levels and 
components of MS, especially carbohydrate disturbances, is 
weaker and affected by impaired renal function. The strong 
associations between RBP4, insulin resistance, and the per-
cent of trunk fat in young subjects were shown to disappear 
in older adults [31]. However, an explanation of the phe-
nomenon is missing.
A significant effect on RBP4 metabolism is impaired 
kidney function, which is frequently found in older adults. 
This supposition is supported by previously published data 
showing normalisation of RBP4 levels after kidney trans-
plant [40–44] and by our results presenting an inverse rela-
tionship between eGFR and RBP4 levels. Unfortunately, 
the lack of assessment of kidney function in the numerous 
published studies may be a reason for the inconsistency of 
available data.
The most significant findings of our study are the asso-
ciations between the levels of RBP4 and hypertriglyceri-
demia, as well as low HDL cholesterol levels (in the mul-
tivariate analysis). This suggests that RBP4 might play an 
Table 3  Comparison of MS factors presence according to RBP4 serum level tertiles, separate for men and women
Bold values indicate statistically significant results
$ For trend; in comparison to the lower quartile: *p < 0.05; **p < 0.01; #p < 0.001
RBP4 tertile Women Men
Lower n = 483 Middle n = 486 Upper n = 478 P Lower n = 530 Middle n = 527 Upper n = 534 P
Metabolic syndrome, 
n (%)
313 (64.8) 332 (68.3) 356 (74.5) < 0.01$ 258 (48.7) 282 (53.5) 323 (60.5) < 0.001$
Visceral obesity, n (%) 437 (90.5) 432 (88.9) 431 (90.2) 0.687 372 (70.2) 384 (72.9) 407 (76.2) < 0.05$
Serum triglycerides 
levels ≥ 150 mg/
dL or treatment of 
hypertriglyceridemia, 
n (%)
128 (26.5) 149 (30.7) 178 (37.2) < 0.001$ 83 (15.7) 101 (19.2) 157 (29.4) < 0.001$
Serum HDL choles-
terol concentration: 
< 40 mg/dL in men 
and < 50 mg/dL in 
women or treatment 
this lipid distur-
bances, n (%)
273 (56.5) 268 (55.1) 287 (60.0) 0.286 220 (41.5) 229 (43.4) 244 (45.7) 0.387
Systolic blood pres-
sure ≥ 130 mmHg or/
and diastolic blood 
pressure ≥ 85 mmHg 
or previously diag-
nosed hypertension, 
n (%)
419 (86.7) 437 (89.9) 431 (90.2) 0.168 434 (81.9) 429 (81.4) 457 (85.6) 0.140
Fasting plasma glu-
cose ≥ 100 mg/dL 
(≥ 5.6 mmol/L) or 
previously diagnosed 
type 2 diabetes, n (%)
194 (40.2) 215 (44.2) 232 (48.5) < 0.01$ 210 (39.6) 251 (47.6) 240 (44.9) < 0.05
No. of metabolic syn-
drome factors
3.0 ± 1.2 3.1 ± 1.2 3.3 ± 1.2** < 0.01 2.5 ± 1.2 2.6 ± 1.2 2.8 ± 1.3# < 0.001
Fig. 1  RBP4 serum levels according to the number of metabolic syn-
drome factors, separated for men and women
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important role in the disturbance of lipid synthesis in the 
liver, related to insulin resistance, and perhaps is a sur-
rogate marker of liver steatosis. It was shown that RBP4 
expression was aberrantly elevated in non-alcoholic fatty 
liver disease (NAFLD) in middle-age human and animal 
models, as well as positively associated with hepatic mito-
chondrial dysfunction combined with increased hepatic 
triglyceride accumulation [45, 46]. In vitro studies showed 
that RBP4 stimulated lipogenesis in HepG2 cells in a 
dose-dependent manner [47]. In line with these findings, 
we demonstrated a higher prevalence of subjects with 
increased FTI > 60 and de Ritis index > 1 in the highest 
RBP4 tertile. However, in multivariate regression analysis, 
both an increased FLI (strongly affected by triglyceride 
level) and the de Ritis index lost statistical significance. 
This suggests that RBP4 is one of many factors influencing 
hepatic lipogenesis and, therefore, its level is not a sensi-
tive marker of NAFLD, at least in older adults.
A strong association between circulating levels of RBP4 
and triglycerides seems to reflect the increased lipogenesis 
in the study subjects. This supposition is strengthened by 
Rocha et al., who demonstrated that on middle-aged, mor-
bidly obese patients, RBP4 independently correlates with 
triglycerides, HDL, LDL, VLDL (very-low-density lipo-
protein), and small-HDL subfractions of cholesterol; all 
particles enriched in triglycerides [17]. There are a couple 
of hypotheses explaining the stimulatory effect of RBP4 on 
lipogenesis. RBP4 has been shown to stimulate synthesis of 
SREBP-1 (sterol regulatory element-binding protein-1) and 
PPARγ (peroxisome proliferator-activated receptor gamma) 
in the liver, both proteins involved in lipogenesis [48]. RBP4 
can also modulate lipid homeostasis indirectly, through reti-
noids, by activation of nuclear retinoid receptors. Finally, 
retinoids and retinol-binding proteins modulate apolipopro-
tein C-III production, an enzyme involved in the catabolism 
of VLDL (an inhibitor of lipoprotein lipase) and β-oxidation 
[49]. In a kinetic study, Verges et al. demonstrated reduced 
VLDL catabolism (VLDL-apolipoprotein B100 fractional 
catabolic rate) in diabetics with increased RBP4 levels [50].
This study has some limitations, such as the lack of vali-
dation of the utilised ELISA kit by a quantitative western 
blot analysis [23], liver sonography, and visceral fat depot 
assessment by DEXA or CT. It should be stressed that such 
measures are difficult to apply in population-based studies 
performed in their place of residence.
Conclusions
In older adult Caucasians, RBP4 serum levels are associated 
with a number of components of MS, independent of sex 
and kidney function. Hypertriglyceridemia as a component 
of MS is most significantly related to RBP4 concentration.
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